Pfizer-backed analysis finds dearth of patient-reported outcomes in trials

An analysis of online data found that only 7.4% of 650 clinical trials for diabetes treatments included patient-reported outcomes, which are supposed to shed light on patients' experiences on the meds. The analytics group Context Matters and drug giant Pfizer ($PFE) partnered on the study, which analyzed data from the NIH's database. The findings were reported today at the 18th Annual International Society for Pharmacoeconomics and Outcomes Research (ISPOR) conference in New Orleans. Report

Suggested Articles

The new solution aims to streamline the incorporation of human genomic data into clinical trial designs.

TriNetX's platform uses EHR data to help drug developers with clinical trial protocol design and study site and participant identification.

The $58 million financing round represents biopharma industry's growing interest in genomics data.